Stockreport

Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

Lixte Biotechnology Holdings, Inc.  (LIXT) 
NASDAQ:AMEX Investor Relations: lixte.com/investor_information_02.php
PDF LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing PASADENA, CA, June 06, 2024 (GLOBE N [Read more]